1
|
Li D, Zhao Y, Zhang C, Wang F, Zhou Y, Jin S. Plasma Exosomes at the Late Phase of Remote Ischemic Pre-conditioning Attenuate Myocardial Ischemia-Reperfusion Injury Through Transferring miR-126a-3p. Front Cardiovasc Med 2021; 8:736226. [PMID: 34917657 PMCID: PMC8669347 DOI: 10.3389/fcvm.2021.736226] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2021] [Accepted: 11/02/2021] [Indexed: 12/12/2022] Open
Abstract
Background: Remote ischemic pre-conditioning (RIPC) alleviated the myocardial ischemia-reperfusion injury, yet the underlying mechanisms remain to be fully elucidated, especially at the late phase. Searching a key component as a transfer carrier may provide a novel insight into RIPC-mediated cardioprotection in the condition of myocardial ischemia-reperfusion. Objective: To investigate the cardioprotective effect of plasma exosomes at the late phase of RIPC and its potential signaling pathways involved. Methods and Results: Exosomes were isolated from the plasma of rats 48 h after the RIPC or control protocol. Although the total plasma exosomes level had no significant change at the late phase of RIPC (RIPC-exosome) compared with the control exosomes (Control-exosome), the RIPC-exosome afforded remarkable protection against myocardial ischemia-reperfusion (MI/R) injury in rats and hypoxia-reoxygenation (H/R) injury in cells. The miRNA array revealed significant enrichment of miR-126a-3p in RIPC-exosome. Importantly, both miR-126a-3p inhibitor and antagonist significantly blunted the cardioprotection of RIPC-exosome in H/R cells and MI/R rats, respectively, while miR-126a-3p mimic and agomir showed significant cardioprotection against H/R injury in cells and MI/R injury in rats. Mechanistically, RIPC-exosome, especially exosomal miR-126a-3p, activated the reperfusion injury salvage kinase (RISK) pathway by enhancing the phosphorylation of Akt and Erk1/2, and simultaneously inhibited Caspase-3 mediated apoptotic signaling. Conclusions: Our findings reveal a novel myocardial protective mechanism that plasma exosomes at the late phase of RIPC attenuate myocardial ischemia-reperfusion injury via exosomal miR-126a-3p.
Collapse
Affiliation(s)
- Danni Li
- Department of Anesthesia, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
| | - Yang Zhao
- Department of Anesthesia, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
| | - Chuyi Zhang
- Department of Anesthesia, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
| | - Fan Wang
- Department of Anesthesia, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
| | - Yan Zhou
- Department of Anesthesia, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
| | - Sanqing Jin
- Department of Anesthesia, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
| |
Collapse
|
2
|
Haraikawa M, Kudo H, Shibuya T, Kogure Y, Takase M, Inage H, Yokota T, Htun H, Tagaya E, Fan R, Houshito H, Taniguchi G, Sakamoto K, Nagahara A. Efficacy of CO₂ Infusion for Preoperative Computed Tomographic Angiography with Computed Tomographic Colonography. Med Sci Monit 2021; 27:e931055. [PMID: 33993185 PMCID: PMC8135977 DOI: 10.12659/msm.931055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
BACKGROUND Computed tomographic colonography (CTC) is useful for patients for whom colonoscopy may be difficult to perform and is widely employed to examine the vasculature prior to colorectal cancer surgery. Computed tomographic angiography (CTA) was shown to be beneficial intraoperatively to manipulate blood vessels and prevent vascular injury. Three-dimensional (3D)-CTA combined with CTC (3D-CTA with CTC) is useful for preoperative evaluations of the anatomy of mesenteric vessels, colon, and lymph nodes. We observed that when the intestine was dilated with carbon dioxide (CO₂), the arteriovenous delineation was often more pronounced than without CO₂. To clarify the effects of gas injection with and without CO₂ on hemodynamics and vascular passage, we compared the effect of contrast for blood vessels. MATERIAL AND METHODS Thirty patients with resectable colorectal cancer who underwent a preoperative CT examination at our institution from January to October 2019 were study participants. Of these, 15 underwent 3D-CTA and 15 had 3D-CTA with CTC. Three board-certified radiologists independently and blindly evaluated 18 blood vessels. CT values for each blood vessel were measured on each image. RESULTS CT values for 3D-CTA with CTC were significantly higher with CO₂ than without CO₂. The quality of 3D-CTA with CTC images for visualization of blood vessels was also significantly greater than that of 3D-CTA, especially those of arterial and intramesenteric venous systems. CONCLUSIONS Based on the higher image quality and CT values obtained by 3D-CTA with CTC for vessels, compared with by 3D-CTA imaging, 3D-CTA with CTC imaging might be useful in evaluating colorectal cancers.
Collapse
Affiliation(s)
- Mayuko Haraikawa
- Department of Gastroenterology, Juntendo University School of Medicine, Tokyo, Japan
| | - Hikaru Kudo
- Department of Radiology, Juntendo University School of Medicine, Tokyo, Japan
| | - Tomoyoshi Shibuya
- Department of Gastroenterology, Juntendo University School of Medicine, Tokyo, Japan
| | - Yosuke Kogure
- Department of Radiology, Juntendo University School of Medicine, Tokyo, Japan
| | - Makoto Takase
- Department of Radiology, Juntendo University School of Medicine, Tokyo, Japan
| | - Hidekazu Inage
- Department of Radiology, Juntendo University School of Medicine, Tokyo, Japan
| | - Takuya Yokota
- Department of Radiology, Juntendo University School of Medicine, Tokyo, Japan
| | - Hanni Htun
- Department of Radiology, Juntendo University School of Medicine, Tokyo, Japan
| | - Eita Tagaya
- Department of Radiology, Juntendo University School of Medicine, Tokyo, Japan
| | - Ruiheng Fan
- Department of Radiology, Juntendo University School of Medicine, Tokyo, Japan
| | - Haruyoshi Houshito
- Department of Radiology, Juntendo University School of Medicine, Tokyo, Japan
| | - Gentaro Taniguchi
- Department of Gastroenterology, Juntendo University School of Medicine, Tokyo, Japan
| | - Kazuhiro Sakamoto
- Department of Coloproctological Surgery, Juntendo University School of Medicine, Tokyo, Japan
| | - Akihito Nagahara
- Department of Gastroenterology, Juntendo University School of Medicine, Tokyo, Japan
| |
Collapse
|
3
|
Yamaguchi T, Watanabe A, Tanaka M, Shiota M, Osada-Oka M, Sano S, Yoshiyama M, Miura K, Kitajima S, Matsunaga S, Tomita S, Iwao H, Izumi Y. A dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, attenuates cardiac dysfunction after myocardial infarction independently of DPP-4. J Pharmacol Sci 2019; 139:112-119. [DOI: 10.1016/j.jphs.2018.12.004] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2018] [Revised: 12/06/2018] [Accepted: 12/11/2018] [Indexed: 01/28/2023] Open
|
4
|
Minghua W, Zhijian G, Chahua H, Qiang L, Minxuan X, Luqiao W, Weifang Z, Peng L, Biming Z, Lingling Y, Zhenzhen W, Jianqing X, Huihui B, Xiaozhong W, Xiaoshu C. Plasma exosomes induced by remote ischaemic preconditioning attenuate myocardial ischaemia/reperfusion injury by transferring miR-24. Cell Death Dis 2018; 9:320. [PMID: 29476052 PMCID: PMC5833738 DOI: 10.1038/s41419-018-0274-x] [Citation(s) in RCA: 95] [Impact Index Per Article: 15.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2017] [Revised: 12/22/2017] [Accepted: 12/28/2017] [Indexed: 01/01/2023]
Abstract
Remote ischaemic preconditioning (RIPC) is well known to protect the myocardium against ischaemia/reperfusion injury (IRI). Exosomes are small extracellular vesicles that have become the key mediators of intercellular communication. Various studies have confirmed that circulating exosomes mediate RIPC. However, the underlying mechanisms for RIPC-induced exosome-mediated cardioprotection remain elusive. In our study, we found that the expression level of miR-24 was higher in exosomes derived from the plasma of rats subjected to RIPC than in exosomes derived from the plasma of control rats in vivo. The rat plasma exosomes could be taken up by H9c2 cells. In addition, miR-24 was present in RIPC-induced exosomes and played a role in reducing oxidative stress-mediated injury and decreasing apoptosis by downregulating Bim expression in H2O2-treated H9c2 cells in vitro. In vivo, miR-24 in RIPC-induced exosomes reduced cardiomyocyte apoptosis, attenuated the infarct size and improved heart function. Furthermore, the apoptosis-reducing effect of miR-24 was counteracted by miR-24 antagomirs or inhibitors both in vitro and in vivo. Therefore, we provided evidence that RIPC-induced exosomes could reduce apoptosis by transferring miR-24 in a paracrine manner and that miR-24 in the exosomes plays a central role in mediating the protective effects of RIPC.
Collapse
Affiliation(s)
- Wen Minghua
- Department of Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, China
| | - Gong Zhijian
- Department of Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, China
| | - Huang Chahua
- Department of Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, China
| | - Liang Qiang
- Jiangxi Province Key Laboratory of Molecular Medicine, Nanchang, China
| | - Xu Minxuan
- Department of Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, China
| | - Wang Luqiao
- Department of Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, China
| | - Zhang Weifang
- Department of Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, China
| | - Lu Peng
- Department of Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, China
| | - Zhan Biming
- Department of Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, China
| | - Yu Lingling
- Department of Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, China
| | - Wang Zhenzhen
- Department of Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, China
| | - Xu Jianqing
- Department of Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, China
| | - Bao Huihui
- Department of Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, China
| | - Wang Xiaozhong
- Department of Laboratory Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, China
| | - Cheng Xiaoshu
- Department of Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
| |
Collapse
|
5
|
Percutaneous carbon dioxide mist treatment has protective effects in experimental myocardial infarction. J Pharmacol Sci 2015; 127:474-80. [PMID: 25906762 DOI: 10.1016/j.jphs.2015.03.009] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2015] [Revised: 03/09/2015] [Accepted: 03/25/2015] [Indexed: 11/23/2022] Open
Abstract
Percutaneous treatment with carbon dioxide (CO2) mist, CO2 gas dissolved in water, contributes to improved cardiac function after myocardial infarction (MI). In this study, we investigated the effects of repeated pretreatment with CO2 mist on cardiac dysfunction after MI. The CO2 mist was generated by a dry mist production unit. The whole body of rats below the axilla was wrapped in a polyethylene bag, which was sealed and filled with the CO2 mist in the draft cabinet for 30 min daily for 7 days. MI was induced by ligation of the coronary artery in untreated (UT), CO2 gas-pretreated (CG), and CO2 mist-pretreated (CM) rats. The infarct size and the increase in oxidative stress due to MI were significantly smaller in the CM rats than in the UT rats. Furthermore, the expression of inflammation-related genes, such as monocyte chemoattractant protein-1, and fibrosis-related genes, such as transforming growth factor-β1, was significantly suppressed in the CM rats. The CM rats had a better left ventricular ejection fraction than the UT rats 7 days after MI. These parameters in the CG rats were the same as in the UT group. Thus, CO2 mist preparative treatment may be potentially useful for the reduction of MI.
Collapse
|
6
|
Repeated remote ischemic conditioning attenuates left ventricular remodeling via exosome-mediated intercellular communication on chronic heart failure after myocardial infarction. Int J Cardiol 2014; 178:239-46. [PMID: 25464262 DOI: 10.1016/j.ijcard.2014.10.144] [Citation(s) in RCA: 124] [Impact Index Per Article: 12.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/13/2014] [Revised: 09/24/2014] [Accepted: 10/22/2014] [Indexed: 01/09/2023]
Abstract
BACKGROUND Remote ischemic conditioning (RIC) by repeated treatment of transient limb ischemia is a clinically applicable method for protecting the heart against injury at the time of reperfusion. In this study, we investigated the effects of repeated RIC on cardiac dysfunction after myocardial infarction (MI). METHODS AND RESULTS At 4weeks after MI, rats were separated into the untreated (UT) group or the RIC-treated group. RIC treatment was performed by 5cycles of 5min of bilateral hindlimb ischemia and 5min of reperfusion once a day for 4weeks. Despite comparable MI size, left ventricular (LV) ejection fraction (LVEF) was significantly improved in the RIC group compared with the UT group. Furthermore, the LVEF in the RIC group was improved, although not significantly, after treatment. RIC treatment also prevented the deterioration of LV diastolic function. MI-induced LV interstitial fibrosis in the boundary region and oxidant stress were significantly attenuated by RIC treatment. MicroRNA-29a (miR-29a), a key regulator of tissue fibrosis, was highly expressed in the exosomes and the marginal area of the RIC group. Even in the differentiated C2C12-derived exosomes, miR-29a expression was significantly increased under hypoxic condition. As well as miR-29a, insulin-like growth factor 1 receptor (IGF-1R) was highly expressed both in the exosomes and remote non-infarcted myocardium of the RIC group. IGF-1R expression was also increased in the C2C12-derived exosomes under hypoxic conditions. CONCLUSIONS Repeated RIC reduces adverse LV remodeling and oxidative stress by MI. Exosome-mediated intercellular communication may contribute to the beneficial effect of RIC treatment.
Collapse
|
7
|
Izumi Y, Yamaguchi T, Yamazaki T, Yamashita N, Nakamura Y, Shiota M, Tanaka M, Sano S, Osada-Oka M, Shimada K, Wanibuchi H, Miura K, Yoshiyama M, Iwao H. Percutaneous carbon dioxide treatment using a gas mist generator enhances the collateral blood flow in the ischemic hindlimb. J Atheroscler Thromb 2014; 22:38-51. [PMID: 25132376 DOI: 10.5551/jat.23770] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
Abstract
AIM Highly concentrated carbon dioxide (CO2) is thought to be useful for ischemic diseases. We investigated whether treatment with a few micrometers of CO2 molecules atomized via two fluidnozzles (CO2 mist) exerts an angiogenic effect in a mouse ischemic hindlimb model. METHODS Mice with unilateral hindlimb ischemia were divided into untreated (UT), 100% CO2 gas alone-treated (CG), mixed air (O2; 20%, N2; 80%) mist-treated (AM) and 100% CO2 mist-treated (CM) groups. The lower body of the mice was encased in a polyethylene bag filled with each gaseous agent using a gas mist generator for 10 minutes daily. RESULTS According to a laser Doppler analysis, the ischemic hindlimb blood flow was persistently higher after the seventh day of induction of ischemia in the CM group than in the UT group. The capillary density was also greater in the CM group on day 28 compared with that observed in the UT group. In addition, the parameters in the AM and CG groups were similar to those obtained in the UT group. The observed effects were abolished by the administration of an inhibitor of nitric oxide synthase (NOS). The vascular endothelial growth factor mRNA expression and protein levels and the phosphorylated endothelial NOS level were increased in the CM group compared with that observed in the UT group. A proteomic analysis using liquid chromatography-tandem mass spectrometry identified novel protein candidates regulated by CO2 mist. CONCLUSION Percutaneous CO2 mist therapy may be useful for treating ischemia-induced angiogenesis.
Collapse
Affiliation(s)
- Yasukatsu Izumi
- Department of Cardiovascular Medicine, Osaka City University Medical School, Osaka, Japan; Department of Pharmacology, Osaka City University Medical School, Osaka, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Yamazaki T, Nakamura Y, Shiota M, Osada-Oka M, Fujiki H, Hanatani A, Shimada K, Miura K, Yoshiyama M, Iwao H, Izumi Y. Tolvaptan attenuates left ventricular fibrosis after acute myocardial infarction in rats. J Pharmacol Sci 2013; 123:58-66. [PMID: 24005048 DOI: 10.1254/jphs.13086fp] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
Abstract
Tolvaptan, a non-peptide V2-receptor antagonist, is a newly developed diuretic agent. Recently, we reported that tolvaptan has diuretic as well as anti-inflammatory and anti-fibrotic actions in chronic heart failure. In this study, we investigated whether tolvaptan has a cardioprotective effect in acute heart failure after myocardial infarction (MI). After MI induction, rats were randomized into 6 groups as follows: vehicle group, group treated with 15 mg∙kg⁻¹∙day⁻¹ furosemide, 2 groups treated with 3 or 10 mg∙kg⁻¹∙day⁻¹ tolvaptan, and 2 groups treated with 15 mg∙kg⁻¹∙day⁻¹ furosemide combined with 3 or 10 mg∙kg⁻¹∙day⁻¹ tolvaptan. Each agent was administered for 2 weeks, and blood pressure levels and infarct sizes were similar in all MI groups. Lower left ventricular end-systolic volumes and greater improvement of left ventricular ejection fraction were observed in the tolvaptan-treated groups compared with the vehicle group. In contrast, furosemide alone did not improve them. Sirius red staining revealed that tolvaptan significantly repressed MI-induced interstitial fibrosis in the left ventricle. MI-induced mRNA expressions related to cardiac load, inflammation, and fibrosis were significantly attenuated in the combination group. The combination treatment also repressed MI-induced mineralocorticoid receptor expression. Tolvaptan, or combination of furosemide and tolvaptan, may improve cardiac function in acute MI.
Collapse
Affiliation(s)
- Takanori Yamazaki
- Department of Cardiovascular Medicine, Osaka City University Medical School, Japan
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Yamazaki T, Izumi Y, Nakamura Y, Yamashita N, Fujiki H, Osada-Oka M, Shiota M, Hanatani A, Shimada K, Iwao H, Yoshiyama M. Tolvaptan Improves Left Ventricular Dysfunction after Myocardial Infarction in Rats. Circ Heart Fail 2012; 5:794-802. [DOI: 10.1161/circheartfailure.112.968750] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Background—
Arginine vasopressin, which promotes the reabsorption of renal water is increased in chronic heart failure. Here, we compared the effects of tolvaptan, a newly developed nonpeptide V
2
receptor antagonist, with those of furosemide, a loop diuretic, and a combination of these 2 agents in rats with left ventricular dysfunction after myocardial infarction (MI).
Methods and Results—
After 10 weeks of MI induction, the rats were separated them into the following 6 groups adjusted to the infarct size: a vehicle group, a group treated with 15 mg·kg
-1
·day
-1
of furosemide, 2 groups treated with 3 or 10 mg·kg
−1
·day
−1
of tolvaptan; and 2 groups treated with 15 mg·kg
−1
·day
−1
of furosemide plus 3 or 10 mg·kg
−1
·day
−1
tolvaptan. Each treatment agent was administered for 4 weeks, and all groups had similar blood pressure levels and infarct size. The tolvaptan-treated groups were found to have lower levels of left ventricular end-diastolic and systolic cardiac volumes than the vehicle group did. Furthermore, the improvement in the ejection fraction in the tolvaptan-treated groups was significantly greater than those in the vehicle group. ED-1 immunostaining and Sirius red staining revealed that tolvaptan significantly repressed MI-induced macrophage infiltration and interstitial fibrosis in the left ventricle, respectively. Tolvaptan attenuated the MI-induced mRNA expressions of atrial and brain natriuretic peptides, monocyte chemotactic protein-1, transforming growth factor-β1, arginine vasopressin V
1a
receptor, and endothelin-1 in the marginal infarct region.
Conclusions—
Tolvaptan may improve cardiac dysfunction after MI, which is partially mediated by the suppression of V
1a
receptor, neurohumoral activation and inflammation.
Collapse
Affiliation(s)
- Takanori Yamazaki
- From the Department of Internal Medicine and Cardiology (T.Y., Y.N., A.H., K.S., M.Y.), and Department of Pharmacology (Y.I., N.Y., M.O., M.S., H.I.), Osaka City University Medical School, Osaka, Japan; and First Institute of New Drug Discovery, Otsuka Pharmaceutical Co. Ltd., Tokushima, Japan (H.F.)
| | - Yasukatsu Izumi
- From the Department of Internal Medicine and Cardiology (T.Y., Y.N., A.H., K.S., M.Y.), and Department of Pharmacology (Y.I., N.Y., M.O., M.S., H.I.), Osaka City University Medical School, Osaka, Japan; and First Institute of New Drug Discovery, Otsuka Pharmaceutical Co. Ltd., Tokushima, Japan (H.F.)
| | - Yasuhiro Nakamura
- From the Department of Internal Medicine and Cardiology (T.Y., Y.N., A.H., K.S., M.Y.), and Department of Pharmacology (Y.I., N.Y., M.O., M.S., H.I.), Osaka City University Medical School, Osaka, Japan; and First Institute of New Drug Discovery, Otsuka Pharmaceutical Co. Ltd., Tokushima, Japan (H.F.)
| | - Naoto Yamashita
- From the Department of Internal Medicine and Cardiology (T.Y., Y.N., A.H., K.S., M.Y.), and Department of Pharmacology (Y.I., N.Y., M.O., M.S., H.I.), Osaka City University Medical School, Osaka, Japan; and First Institute of New Drug Discovery, Otsuka Pharmaceutical Co. Ltd., Tokushima, Japan (H.F.)
| | - Hiroyuki Fujiki
- From the Department of Internal Medicine and Cardiology (T.Y., Y.N., A.H., K.S., M.Y.), and Department of Pharmacology (Y.I., N.Y., M.O., M.S., H.I.), Osaka City University Medical School, Osaka, Japan; and First Institute of New Drug Discovery, Otsuka Pharmaceutical Co. Ltd., Tokushima, Japan (H.F.)
| | - Mayuko Osada-Oka
- From the Department of Internal Medicine and Cardiology (T.Y., Y.N., A.H., K.S., M.Y.), and Department of Pharmacology (Y.I., N.Y., M.O., M.S., H.I.), Osaka City University Medical School, Osaka, Japan; and First Institute of New Drug Discovery, Otsuka Pharmaceutical Co. Ltd., Tokushima, Japan (H.F.)
| | - Masayuki Shiota
- From the Department of Internal Medicine and Cardiology (T.Y., Y.N., A.H., K.S., M.Y.), and Department of Pharmacology (Y.I., N.Y., M.O., M.S., H.I.), Osaka City University Medical School, Osaka, Japan; and First Institute of New Drug Discovery, Otsuka Pharmaceutical Co. Ltd., Tokushima, Japan (H.F.)
| | - Akihisa Hanatani
- From the Department of Internal Medicine and Cardiology (T.Y., Y.N., A.H., K.S., M.Y.), and Department of Pharmacology (Y.I., N.Y., M.O., M.S., H.I.), Osaka City University Medical School, Osaka, Japan; and First Institute of New Drug Discovery, Otsuka Pharmaceutical Co. Ltd., Tokushima, Japan (H.F.)
| | - Kenei Shimada
- From the Department of Internal Medicine and Cardiology (T.Y., Y.N., A.H., K.S., M.Y.), and Department of Pharmacology (Y.I., N.Y., M.O., M.S., H.I.), Osaka City University Medical School, Osaka, Japan; and First Institute of New Drug Discovery, Otsuka Pharmaceutical Co. Ltd., Tokushima, Japan (H.F.)
| | - Hiroshi Iwao
- From the Department of Internal Medicine and Cardiology (T.Y., Y.N., A.H., K.S., M.Y.), and Department of Pharmacology (Y.I., N.Y., M.O., M.S., H.I.), Osaka City University Medical School, Osaka, Japan; and First Institute of New Drug Discovery, Otsuka Pharmaceutical Co. Ltd., Tokushima, Japan (H.F.)
| | - Minoru Yoshiyama
- From the Department of Internal Medicine and Cardiology (T.Y., Y.N., A.H., K.S., M.Y.), and Department of Pharmacology (Y.I., N.Y., M.O., M.S., H.I.), Osaka City University Medical School, Osaka, Japan; and First Institute of New Drug Discovery, Otsuka Pharmaceutical Co. Ltd., Tokushima, Japan (H.F.)
| |
Collapse
|